Ok Biotech Co., Ltd. AI Stock Analysis
Ok Biotech Co., Ltd. (4155) AI Stock Analysis
Ok Biotech Co., Ltd.
(TWSE:4155)
Ok Biotech earns a moderate score. Fundamentals are the dominant factor and remain average: the balance sheet is solid with equity covering two-thirds of assets, and 2025 brought a sharp gross margin recovery and a near-fivefold jump in operating cash flow, but revenue is flat, earnings are volatile, return on equity is just 3.3%, and free cash flow stays negative as debt-funded expansion continues. Supporting the score is strong technical momentum, with the price above all major moving averages and a positive MACD, alongside an inexpensive 10.5x P/E and a 1.68% dividend yield. The key risk is whether the expanded asset base finally converts into consistent revenue growth and positive free cash flow.
Ok Biotech Co., Ltd. (4155) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.06B
- Dividend Yield
- 1.71%
- Average Volume (3M)
- 562.85K
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 0.04
- Revenue Growth
- -10.90%
- EPS Growth
- ―
- Country
- TW
- Employees
- 62
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Ok Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
OK Biotech Co., Ltd., established in 2006 and based in Hsinchu City, Taiwan, is a global producer and vendor of blood glucose meters. Its product line further encompasses nebulizers, glucometers, blood sugar meters, blood glucose test strips, and per...
Ok Biotech Co., Ltd. Financial Statement Overview
Summary
A mixed but stabilizing profile. The balance sheet is the anchor, with equity funding about 65% of assets and debt-to-equity of 0.41, though borrowings have tripled from NT$333m to NT$1.03bn in two years to fund expansion. Profitability improved in 2025 — gross margin jumped to 27.6% from 16.5% and operating profit nearly doubled to NT$108m — while operating cash flow surged to NT$320m, covering net income 3.9 times. Offsetting these gains are flat-to-declining revenue (NT$1.56bn, essentially unchanged versus five years ago), erratic earnings, a weak 3.3% return on equity, and free cash flow that remains negative (-NT$90m) for the fifth time in six years amid a heavy capex cycle.
Income Statement
51NeutralBalance Sheet
62PositiveCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.54B | 1.56B | 1.67B | 1.19B | 1.48B | 1.26B |
| Gross Profit | 478.56M | 429.25M | 275.65M | 196.88M | 344.96M | 186.83M |
| EBITDA | 357.39M | 201.51M | 205.76M | 87.24M | 247.47M | 85.45M |
| Net Income | 242.24M | 82.45M | 93.97M | 2.95M | 143.46M | 31.42M |
Balance Sheet | ||||||
| Total Assets | 3.99B | 3.85B | 3.70B | 3.07B | 3.06B | 2.81B |
| Cash, Cash Equivalents and Short-Term Investments | 382.88M | 327.06M | 290.50M | 365.34M | 636.64M | 644.63M |
| Total Debt | 1.04B | 1.03B | 779.43M | 332.98M | 780.64M | 735.74M |
| Total Liabilities | 1.42B | 1.27B | 1.13B | 672.26M | 1.21B | 1.11B |
| Stockholders Equity | 2.52B | 2.51B | 2.49B | 2.40B | 1.84B | 1.70B |
Cash Flow | ||||||
| Free Cash Flow | 257.46M | -89.57M | -308.81M | -434.15M | -53.72M | -64.57M |
| Operating Cash Flow | 490.95M | 319.57M | 65.90M | 2.93M | 240.53M | 21.90M |
| Investing Cash Flow | -223.08M | -398.50M | -444.93M | -358.38M | -294.23M | -174.46M |
| Financing Cash Flow | -73.85M | 113.04M | 338.02M | 82.06M | 50.27M | 185.69M |
Ok Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:413868Neutral
TW:410667.5Neutral- TW:415564Neutral
TW:178452Neutral
TW:410847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4138 | 68Neutral | TWD 2.15B | 15.50 | ― | 7.81% | -1.10% | -16.90% |
| TW:4106 | 68Neutral | TWD 2.36B | 12.70 | ― | 4.27% | 7.96% | 86.06% |
| TW:4155 | 64Neutral | TWD 2.19B | 10.29 | ― | 1.71% | -10.90% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1784 | 52Neutral | TWD 2.38B | 39.56 | ― | 1.87% | 5.41% | -19.02% |
| TW:4108 | 47Neutral | TWD 2.06B | -48.21 | ― | ― | 3.62% | 34.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4155 | Ok Biotech Co., Ltd. | 17.50 | 2.12 | 13.81% | |
| TW:1784 | Bionet Corp. | 47.00 | -50.18 | -51.64% | |
| TW:4106 | Wellell Inc. | 23.40 | 2.78 | 13.47% | |
| TW:4108 | Phytohealth Corporation | 10.35 | -3.90 | -27.37% | |
| TW:4138 | Dynamic Medical Technologies Inc. | 53.80 | -5.91 | -9.90% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 71.20 | -1.47 | -2.02% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026